PHILADELPHIA - Many types of tumors grow because of over-expression or a mutation of a protein called the epidermal growth factor receptor (EGFR), normally regulated by a hormone-like peptide called the epidermal growth factor (EGF). Several cancer drugs, including Herceptin, Erbitux, Iressa and Tarceva fight tumors by blocking EGFR and related receptors, notes Mark A.
Perelman School of Medicine
Neil Fishman and Arthur Caplan of the School of Medicine discuss employers’ flu-vaccination requirements.
Arthur Caplan of the School of Medicine is cited for expert opinion on controversial California cancer treatments.
J. Larry Jameson is named dean of the University of Pennsylvania School of Medicine and executive vice president for the Health System.
Jonathan Moreno of the School of Medicine and the School of Arts and Sciences authors an op-ed on stem-cell legislation.
Timothy Rebbeck and Susan Domchek of the School of Medicine are cited for research on certain surgeries’ effect on cancer-survival rates.
Women who have inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes have substantially elevated risks of developing breast and ovarian cancer. A study that will appear in the September 1 issue of The Journal of the American Medical Association (JAMA) reports that women with these inherited mutations who have had a prophylactic mastectomy or salpingo-oophorectomy (removal of the fallopian tubes and ovaries) had an associated decreased risk of breast cancer and ovarian cancer.
Leslie Shaw of the School of Medicine is cited for his research on an early Alzheimer’s diagnostic tool.